[Translation] A single-center, randomized, open-label, fasting single-dose, two-dose, three-sequence, three-period, partially repeated crossover and fed single-dose, two-dose, two-sequence, two-period crossover bioequivalence study of fexofenadine hydrochloride oral suspension in healthy Chinese adult subjects
主要研究目的:考察单次口服(空腹/餐后)受试制剂盐酸非索非那定口服混悬液(规格:120ml:0.72g)与参比制剂盐酸非索非那定口服混悬液(Children's Allegra Allergy®,规格:30mg/5mL)在中国健康人体的相对生物利用度,分析两种制剂的药代动力学参数,评价两制剂的生物等效性,为该药的申报及临床用药提供参考依据。
次要研究目的:评价单次口服(空腹/餐后)受试制剂和参比制剂盐酸非索非那定口服混悬液在中国成年健康受试者中的安全性。
[Translation] The primary study objective was to investigate the relative bioavailability of a single oral dose (fasting/fed) of the test formulation, fexofenadine hydrochloride oral suspension (120ml: 0.72g), compared to the reference formulation, fexofenadine hydrochloride oral suspension (Children's Allegra Allergy®, 30mg/5mL), in healthy Chinese adults. The pharmacokinetic parameters of the two formulations were analyzed, and their bioequivalence was evaluated to provide a reference for drug application and clinical use.
The secondary study objective was to evaluate the safety of a single oral dose (fasting/fed) of the test formulation and the reference formulation, fexofenadine hydrochloride oral suspension, in healthy Chinese adults.